405 related articles for article (PubMed ID: 33926411)
1. Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Smith SM; Sabnis HS; Lewis RW; Effinger KE; Bergsagel J; Patterson B; Mertens A; Sakamoto KM; Schapira L; Castellino SM
BMC Cancer; 2021 Apr; 21(1):474. PubMed ID: 33926411
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
6. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
7. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
8. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
9. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Lejniece S; Udre I; Rivkina A
Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
[TBL] [Abstract][Full Text] [Related]
10. Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias.
Zou JY; Huang SM; Zhoub HX; Xu MZ; Sun AN; Wu DP; Xue SL; Zhang TT
Hematology; 2023 Dec; 28(1):2237790. PubMed ID: 37477259
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
12. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib.
Morita K; Kantarjian HM; Sasaki K; Issa GC; Jain N; Konopleva M; Short NJ; Takahashi K; DiNardo CD; Kadia TM; Garcia-Manero G; Daver N; Montalban Bravo G; Cortes JE; Ravandi F; Jabbour E
Cancer; 2021 Aug; 127(15):2641-2647. PubMed ID: 33823073
[TBL] [Abstract][Full Text] [Related]
13. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?
Buhl Rasmussen AS; Andersen CL; Weimann A; Yang T; Tron C; Gandemer V; Dalhoff K; Rank CU; Schmiegelow K
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):225-234. PubMed ID: 38345044
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary hypertension in patients with chronic myeloid leukemia.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Sun BJ; Park JH; Jeong JO; Jo DY
Medicine (Baltimore); 2021 Aug; 100(33):e26975. PubMed ID: 34414970
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib in the treatment of chronic myeloid leukemia and philadelphia chromosome positive acute lymphoblastic leukemia.
Pavlovsky C; Chan O; Talati C; Pinilla-Ibarz J
Future Oncol; 2019 Jan; 15(3):257-269. PubMed ID: 30251548
[TBL] [Abstract][Full Text] [Related]
17. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
[TBL] [Abstract][Full Text] [Related]
18. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Novo G; Di Lisi D; Bronte E; Macaione F; Accurso V; Badalamenti G; Rinaldi G; Siragusa S; Novo S; Russo A
Oncology; 2020; 98(7):445-451. PubMed ID: 32348984
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
